Trial Profile
A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2020
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary) ; Corticotropin (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Mallinckrodt plc
- 01 May 2020 Primary endpoint, Physical subscale score of the Multiple Sclerosis Impact Scale, v.1 (MSIS-29v1), has been met as per results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 27 Feb 2020 According to a Mallinckrodt plc media release, patients were followed for up to 24 months, and a minimum of six months at 31 U.S. sites.